Document Detail


Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart.
MedLine Citation:
PMID:  11861418     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Inhibition of xanthine oxidase (XO) in failing hearts improves cardiac efficiency by an unknown mechanism. We hypothesized that this energetic effect is due to reduced oxidative stress and critically depends on nitric oxide synthase (NOS) activity, reflecting a balance between generation of nitric oxide (NO) and reactive oxygen species. In dogs with pacing-induced heart failure (HF), ascorbate (1000 mg) mimicked the beneficial energetic effects of allopurinol, increasing both contractility and efficiency, suggesting an antioxidant mechanism. Allopurinol had no additive effect beyond that of ascorbate. Crosstalk between XO and NOS signaling was assessed. NOS inhibition with N(G)-monomethyl-L-arginine (L-NMMA; 20 mg/kg) had no effect on basal contractility or efficiency in HF, but prevented the +26.2+/-3.5% and +66.5+/-17% enhancements of contractility and efficiency, respectively, observed with allopurinol alone. Similarly, improvements in contractility and energetics due to ascorbate were also inhibited by L-NMMA. Because of the observed NOS-XO crosstalk, we predicted that in normal hearts NOS inhibition would uncover a depression of energetics caused by XO activity. In normal conscious dogs, L-NMMA increased myocardial oxygen consumption (MVO2) while lowering left ventricular external work, reducing efficiency by 31.1+/-3.8% (P<0.005). Lowered efficiency was reversed by XO inhibition (allopurinol, 200 mg) or by ascorbate without affecting cardiac load or systemic hemodynamics. Single-cell immunofluorescence detected XO protein in cardiac myocytes that was enhanced in HF, consistent with autocrine signaling. These data show that both NOS and XO signaling systems participate in the regulation of myocardial mechanical efficiency and that upregulation of XO relative to NOS contributes to mechanoenergetic uncoupling in heart failure.
Authors:
Walter F Saavedra; Nazareno Paolocci; Marcus E St John; Michel W Skaf; Garrick C Stewart; Jin-Sheng Xie; Robert W Harrison; Joshua Zeichner; Daniel Mudrick; Eduardo Marbán; David A Kass; Joshua M Hare
Related Documents :
23390048 - Trends in cardiovascular mortality and hospitalisations, and potential contribution of ...
11826838 - Balance and imbalance of regional myocardial contractile function and blood flow.
1428738 - Effects of vasoconstrictors on isolated rabbit coronary arteries exposed to isotonic io...
3675508 - Ultrasound techniques in space medicine.
8557918 - Familial cardiomyopathy underlies syndrome of right bundle branch block, st segment ele...
20451358 - Broken heart syndrome: tako tsubo cardiomyopathy associated with an overdose of the ser...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Circulation research     Volume:  90     ISSN:  1524-4571     ISO Abbreviation:  Circ. Res.     Publication Date:  2002 Feb 
Date Detail:
Created Date:  2002-02-25     Completed Date:  2002-02-27     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0047103     Medline TA:  Circ Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  297-304     Citation Subset:  IM    
Affiliation:
Department of Medicine, Cardiology Division and Institute of Molecular Cardiobiology, Johns Hopkins Medical Institutions, Baltimore, Md, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Allopurinol / administration & dosage
Animals
Antioxidants / administration & dosage
Ascorbic Acid / administration & dosage
Cardiac Pacing, Artificial
Cardiomyopathy, Dilated / drug therapy,  etiology*,  physiopathology*
Dogs
Energy Metabolism / drug effects
Fluorescent Antibody Technique
Free Radical Scavengers / administration & dosage
Hemodynamics / drug effects
Infusions, Intravenous
Myocardial Contraction / drug effects
Myocardium / enzymology,  pathology
Nitric Oxide Synthase / antagonists & inhibitors,  metabolism*
Signal Transduction* / drug effects
Xanthine Oxidase / antagonists & inhibitors,  metabolism*
omega-N-Methylarginine / administration & dosage
Grant Support
ID/Acronym/Agency:
K08 HL-03238/HL/NHLBI NIH HHS; P50 HL52307/HL/NHLBI NIH HHS; R01 HL-65455/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Antioxidants; 0/Free Radical Scavengers; 17035-90-4/omega-N-Methylarginine; 315-30-0/Allopurinol; 50-81-7/Ascorbic Acid; EC 1.14.13.39/Nitric Oxide Synthase; EC 1.17.3.2/Xanthine Oxidase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Spatiotemporal transition to conduction block in canine ventricle.
Next Document:  The Na+-Ca2+ exchanger is essential for the action of cardiac glycosides.